RT Journal Article
SR Electronic
T1 Dynamics of abdominal symptoms during the start of a new therapy with Elexacaftor/Tezacaftor/Ivacaftor using the novel CFAbd-day2day questionnaire
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.31.23293088
DO 10.1101/2023.07.31.23293088
A1 Mainz, Jochen G.
A1 Barucha, Anton
A1 Huang, Pu
A1 Bechinger, Lilith
A1 Duckstein, Franziska
A1 Polte, Louise
A1 Sadrieh, Pauline
A1 Nährlich, Lutz
A1 Eickmeier, Olaf
A1 van Dullemen, Suzanne
A1 Eschenhagen, Patience
A1 Schwarz, Carsten
A1 Lüth, Stefan
A1 Zagoya, Carlos
A1 Graepler-Mainka, Ute
YR 2023
UL http://medrxiv.org/content/early/2023/08/02/2023.07.31.23293088.abstract
AB Background Elexacaftor-tezacaftor-ivacaftor (ETI) is a novel highly effective CFTR modulator combination proven to improve lung function and body weight in people with Cystic Fibrosis (pwCF) carrying a F508del mutation. Recently, we revealed significant reductions of abdominal symptoms (AS) in German, British and Irish pwCF after 24-26 weeks of ETI using the CFAbd-Score, the first PROM specifically developed and validated for pwCF following FDA guidelines. Notably, many pwCF reported marked changes in their AS during the first days of the new treatment. To capture these immediate effects, we developed the CFAbd-day2day, a CF-specific GI-diary, following FDA and COSMIN guidelines.Aims To prospectively capture immediate dynamics of AS using the CFAbd-day2day 14 days before and 14-28 days after ETI initiation. In addition, we aim here to provide validation steps of the novel PROM concerning sensitivity to changes.Methods To develop the CFAbd-day2day, focus groups (community voice=pwCF and their proxies and CF specialists from different fields) were repeatedly consulted. Before and under the new ETI therapy pwCF prospectively scored AS on a daily basis with the CFAbd-day2day.Results Altogether, n=45 pwCF attended in 5 CF centers prospectively completed the CFAbd-day2day before (mean±sd: −14±7 days) and after (mean±sd: 28±23 days) ETI initiation. Whereas cumulative scores significantly decreased during the 3-4-week time frame after ETI initiation, compared to the two weeks prior to therapy, many patients who revealed a relatively stable level of AS before ETI reported changes during the first days of treatment with the highly effective CFTR modulators. Items like pain and flatulence increased in up to 21% of patients during the first 14 days of therapy but they improved during days 15-27.Conclusion The CFAbd-day2day, specifically developed and in process of validation to prospectively capture GI symptoms in pwCF, provides new substantial insights into the dynamics of AS in pwCF receiving a new treatment with ETI. The novel tool is also helpful to prospectively monitor patients with specific GI problems. International implementation and further validation steps of the diary are ongoing.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03052283Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been conducted in strict accordance with the ethical guidelines in the Declaration of Helsinki and, for Germany, it was approved by the Brandenburg Medical School ethics committee (Prof. Dr. Dr. Kurt J.G. Schmailzl, registration number: E-01-20200519).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe raw data supporting the conclusions of this article will be made available by the authors, without undue reservation